Piroxicam - Generic Drug Details

✉ Email this page to a colleague

What are the generic drug sources for piroxicam and what is the scope of freedom to operate?

Piroxicam is the generic ingredient in two branded drugs marketed by Pfizer, Breckenridge, Cycle, Egis, Flamingo Pharms, Hikma, Ivax Sub Teva Pharms, Micro Labs, Mylan, Norvium Bioscience, Nostrum Labs Inc, SCS, Strides Pharma, Sun Pharm Industries, Teva, Teva Pharms, Unichem, Watson Labs, and Zydus Lifesciences, and is included in twenty-three NDAs. Additional information is available in the individual branded drug profile pages.

There are sixteen drug master file entries for piroxicam. Thirteen suppliers are listed for this compound.

Summary for piroxicam

US Patents:	0
Tradenames:	2
Applicants:	19
NDAs:	23
Drug Master File Entries:	16
Finished Product Suppliers / Packagers:	13
Raw Ingredient (Bulk) Api Vendors:	160
Clinical Trials:	28
Patent Applications:	8,043
Drug Prices:	Drug price trends for piroxicam
Drug Sales Revenues:	Drug sales revenues for piroxicam
What excipients (inactive ingredients) are in piroxicam?	piroxicam excipients list
DailyMed Link:	piroxicam at DailyMed

See drug prices for piroxicam

See drug sales revenues for piroxicam

Recent Clinical Trials for piroxicam

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Monastir	Phase 2
Mansoura University	Phase 2
Farjad Zafar	Phase 4

See all piroxicam clinical trials

Pharmacology for piroxicam

Drug Class	Nonsteroidal Anti-inflammatory Drug
Mechanism of Action	Cyclooxygenase Inhibitors

Medical Subject Heading (MeSH) Categories for piroxicam

Anti-Inflammatory Agents, Non-Steroidal
Cyclooxygenase Inhibitors

US Patents and Regulatory Information for piroxicam

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ivax Sub Teva Pharms	PIROXICAM	piroxicam	CAPSULE;ORAL	074148-002	Jun 3, 1996		DISCN	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Micro Labs	PIROXICAM	piroxicam	CAPSULE;ORAL	206152-002	Dec 29, 2017	AB	RX	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Teva	PIROXICAM	piroxicam	CAPSULE;ORAL	073638-001	Jan 28, 1994		DISCN	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for piroxicam

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer	FELDENE	piroxicam	CAPSULE;ORAL	018147-002	Apr 6, 1982	⤷ Sign Up	⤷ Sign Up
Pfizer	FELDENE	piroxicam	CAPSULE;ORAL	018147-003	Apr 6, 1982	⤷ Sign Up	⤷ Sign Up
Pfizer	FELDENE	piroxicam	CAPSULE;ORAL	018147-002	Apr 6, 1982	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.